Detailed description page of THPdb

Details of Th1032 which contains 8 entries.

Entry 1
(1) Primary information
ID 1234
ThPP ID Th1032
Therapeutic Peptide/Protein Name Coagulation factor VIIa
Sequence ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification Ib
Molecular Weight 45079.1
Chemical Formula C1972H3076N560O597S28
Isoelectric Point 6.09
Hydrophobicity -0.311
Melting Point (℃) 58
Half Life N.A.
Description Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity N.A.
Metabolism N.A.
Absorption N.A.
Volume of Distribution 121 Â± 30 mL/kg [adults]
Clearance 33 - 37 mL/h x kg [healthy]
Categories Coagulants
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction Autoplex T (anti-inhibitor coagulant complex)
Target Coagulation factor X,Serine protease hepsin,Tissue factor pathway inhibitor,Vitamin K-dependent gamma-carboxylase,Coagulation factor VII,Tissue factor
Information of corresponding available drug in the market
Brand Name NovoSeven
Company Novo Nordisk
Brand Discription NovoSeven is recombinant human coagulation Factor VIIa, intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven (coagulation factor viia recombinant) is a vitamin K-dependent glycoprotein consisting of 4
Prescribed for For treatment and prevention of bleeding in surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmannâ€™s thrombasthenia who have a decreased or absent response
Chemical Name N.A.
Formulation Each vial contains approximately 0. 6 mg/mL NovoSeven (coagulation factor viia recombinant) (corresponding to 600 _g/mL). The reconstituted vials have a pH of approximately 5. 5 in sodium chloride (3 mg/mL), calcium chloride dihydrate (1. 5 mg/mL), glycyl
Physcial Appearance Sterile, white lyophilized powder
Route of Administration Injection
Recommended Dosage For bleeding episodes, the recommended dose of NovoSeven (coagulation factor viia (recombinant)) for hemophilia A or B patients with inhibitors is 90 _g/kg given every two hours by bolus infusion until hemostasis is achieved, or until thehemostasis has been acheived.
Contraindication Hypersensitivity
Side Effects Rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; bleeding at the injection site; bloody stools; calf or stomach pain, tenderness, or swelling; chest pain; confusion; dizziness; fainting; numbness.
Useful Link http://www.novosevenrt.com
PubMed ID 16418464
3-D Structure Th1032 (View) or (Download)

Entry 2
(2) Primary information
ID 1235
ThPP ID Th1032
Therapeutic Peptide/Protein Name Coagulation factor VIIa
Sequence ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification Ib
Molecular Weight 45079.1
Chemical Formula C1972H3076N560O597S28
Isoelectric Point 6.09
Hydrophobicity -0.311
Melting Point (℃) 58
Half Life N.A.
Description Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity N.A.
Metabolism N.A.
Absorption N.A.
Volume of Distribution 153 Â± 29 mL/kg [children]
Clearance 1375 Â± 396 mL/hr [severe hemophilia A male children]
Categories Thrombotic Agents
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction Bebulin VH (factor ix complex)
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link http://www.novonordisk.co.in/documents/article_page/document/Haemostasis_FAQ.asp
PubMed ID 16418464
3-D Structure Th1032 (View) or (Download)

Entry 3
(3) Primary information
ID 1236
ThPP ID Th1032
Therapeutic Peptide/Protein Name Coagulation factor VIIa
Sequence ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification Ib
Molecular Weight 45079.1
Chemical Formula C1972H3076N560O597S28
Isoelectric Point 6.09
Hydrophobicity -0.311
Melting Point (℃) 58
Half Life N.A.
Description Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity N.A.
Metabolism N.A.
Absorption N.A.
Volume of Distribution 280 to 290 mL/kg [congenital Factor VII deficiency]
Clearance 57.3 Â± 9.5 mL/hr/kg [severe hemophilia A male children]
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction Febia NF (anti-inhibitor coagulant complex)
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link http://www.rxlist.com/novoseven-drug.htm
PubMed ID 16418464
3-D Structure Th1032 (View) or (Download)

Entry 4
(4) Primary information
ID 1237
ThPP ID Th1032
Therapeutic Peptide/Protein Name Coagulation factor VIIa
Sequence ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification Ib
Molecular Weight 45079.1
Chemical Formula C1972H3076N560O597S28
Isoelectric Point 6.09
Hydrophobicity -0.311
Melting Point (℃) 58
Half Life N.A.
Description Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity N.A.
Metabolism N.A.
Absorption N.A.
Volume of Distribution N.A.
Clearance 2767 Â± 385 mL/hr [severe hemophilia A men]
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction Feiba VH (anti-inhibitor coagulant complex)
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link http://www.drugs.com/cdi/novoseven.html
PubMed ID 16418464
3-D Structure Th1032 (View) or (Download)

Entry 5
(5) Primary information
ID 1238
ThPP ID Th1032
Therapeutic Peptide/Protein Name Coagulation factor VIIa
Sequence ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification Ib
Molecular Weight 45079.1
Chemical Formula C1972H3076N560O597S28
Isoelectric Point 6.09
Hydrophobicity -0.311
Melting Point (℃) 58
Half Life N.A.
Description Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity N.A.
Metabolism N.A.
Absorption N.A.
Volume of Distribution N.A.
Clearance 37.6 Â± 13.1 mL/hr/kg [severe hemophilia A men]
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction Konyne 80 (factor ix complex)
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link http://www.rxlist.com/novoseven-drug/indications-dosage.htm
PubMed ID 16418464
3-D Structure Th1032 (View) or (Download)

Entry 6
(6) Primary information
ID 1239
ThPP ID Th1032
Therapeutic Peptide/Protein Name Coagulation factor VIIa
Sequence ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification Ib
Molecular Weight 45079.1
Chemical Formula C1972H3076N560O597S28
Isoelectric Point 6.09
Hydrophobicity -0.311
Melting Point (℃) 58
Half Life N.A.
Description Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity N.A.
Metabolism N.A.
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction Profilnine SD (factor ix complex)
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 16418464
3-D Structure Th1032 (View) or (Download)

Entry 7
(7) Primary information
ID 1240
ThPP ID Th1032
Therapeutic Peptide/Protein Name Coagulation factor VIIa
Sequence ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification Ib
Molecular Weight 45079.1
Chemical Formula C1972H3076N560O597S28
Isoelectric Point 6.09
Hydrophobicity -0.311
Melting Point (℃) 58
Half Life N.A.
Description Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity N.A.
Metabolism N.A.
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction Proplex T (factor ix complex)
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 16418464
3-D Structure Th1032 (View) or (Download)

Entry 8
(8) Primary information
ID 1241
ThPP ID Th1032
Therapeutic Peptide/Protein Name Coagulation factor VIIa
Sequence ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification Ib
Molecular Weight 45079.1
Chemical Formula C1972H3076N560O597S28
Isoelectric Point 6.09
Hydrophobicity -0.311
Melting Point (℃) 58
Half Life N.A.
Description Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity N.A.
Metabolism N.A.
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction Brilinta (ticagrelor)
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 16418464
3-D Structure Th1032 (View) or (Download)

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

(1) Primary information
Entry 1
ID	1234
ThPP ID	Th1032
Therapeutic Peptide/Protein Name	Coagulation factor VIIa
Sequence	ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	45079.1
Chemical Formula	C1972H3076N560O597S28
Isoelectric Point	6.09
Hydrophobicity	-0.311
Melting Point (℃)	58
Half Life	N.A.
Description	Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease	For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics	To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action	NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity	N.A.
Metabolism	N.A.
Absorption	N.A.
Volume of Distribution	121 Â± 30 mL/kg [adults]
Clearance	33 - 37 mL/h x kg [healthy]
Categories	Coagulants
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	Autoplex T (anti-inhibitor coagulant complex)
Target	Coagulation factor X,Serine protease hepsin,Tissue factor pathway inhibitor,Vitamin K-dependent gamma-carboxylase,Coagulation factor VII,Tissue factor
Information of corresponding available drug in the market
Brand Name	NovoSeven
Company	Novo Nordisk
Brand Discription	NovoSeven is recombinant human coagulation Factor VIIa, intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven (coagulation factor viia recombinant) is a vitamin K-dependent glycoprotein consisting of 4
Prescribed for	For treatment and prevention of bleeding in surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmannâ€™s thrombasthenia who have a decreased or absent response
Chemical Name	N.A.
Formulation	Each vial contains approximately 0. 6 mg/mL NovoSeven (coagulation factor viia recombinant) (corresponding to 600 _g/mL). The reconstituted vials have a pH of approximately 5. 5 in sodium chloride (3 mg/mL), calcium chloride dihydrate (1. 5 mg/mL), glycyl
Physcial Appearance	Sterile, white lyophilized powder
Route of Administration	Injection
Recommended Dosage	For bleeding episodes, the recommended dose of NovoSeven (coagulation factor viia (recombinant)) for hemophilia A or B patients with inhibitors is 90 _g/kg given every two hours by bolus infusion until hemostasis is achieved, or until thehemostasis has been acheived.
Contraindication	Hypersensitivity
Side Effects	Rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; bleeding at the injection site; bloody stools; calf or stomach pain, tenderness, or swelling; chest pain; confusion; dizziness; fainting; numbness.
Useful Link	http://www.novosevenrt.com
PubMed ID	16418464
3-D Structure	Th1032 (View) or (Download)

(2) Primary information
Entry 2
ID	1235
ThPP ID	Th1032
Therapeutic Peptide/Protein Name	Coagulation factor VIIa
Sequence	ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	45079.1
Chemical Formula	C1972H3076N560O597S28
Isoelectric Point	6.09
Hydrophobicity	-0.311
Melting Point (℃)	58
Half Life	N.A.
Description	Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease	For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics	To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action	NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity	N.A.
Metabolism	N.A.
Absorption	N.A.
Volume of Distribution	153 Â± 29 mL/kg [children]
Clearance	1375 Â± 396 mL/hr [severe hemophilia A male children]
Categories	Thrombotic Agents
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	Bebulin VH (factor ix complex)
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://www.novonordisk.co.in/documents/article_page/document/Haemostasis_FAQ.asp
PubMed ID	16418464
3-D Structure	Th1032 (View) or (Download)

(3) Primary information
Entry 3
ID	1236
ThPP ID	Th1032
Therapeutic Peptide/Protein Name	Coagulation factor VIIa
Sequence	ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	45079.1
Chemical Formula	C1972H3076N560O597S28
Isoelectric Point	6.09
Hydrophobicity	-0.311
Melting Point (℃)	58
Half Life	N.A.
Description	Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease	For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics	To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action	NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity	N.A.
Metabolism	N.A.
Absorption	N.A.
Volume of Distribution	280 to 290 mL/kg [congenital Factor VII deficiency]
Clearance	57.3 Â± 9.5 mL/hr/kg [severe hemophilia A male children]
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	Febia NF (anti-inhibitor coagulant complex)
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://www.rxlist.com/novoseven-drug.htm
PubMed ID	16418464
3-D Structure	Th1032 (View) or (Download)

(4) Primary information
Entry 4
ID	1237
ThPP ID	Th1032
Therapeutic Peptide/Protein Name	Coagulation factor VIIa
Sequence	ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	45079.1
Chemical Formula	C1972H3076N560O597S28
Isoelectric Point	6.09
Hydrophobicity	-0.311
Melting Point (℃)	58
Half Life	N.A.
Description	Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease	For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics	To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action	NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity	N.A.
Metabolism	N.A.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	2767 Â± 385 mL/hr [severe hemophilia A men]
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	Feiba VH (anti-inhibitor coagulant complex)
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://www.drugs.com/cdi/novoseven.html
PubMed ID	16418464
3-D Structure	Th1032 (View) or (Download)

(5) Primary information
Entry 5
ID	1238
ThPP ID	Th1032
Therapeutic Peptide/Protein Name	Coagulation factor VIIa
Sequence	ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	45079.1
Chemical Formula	C1972H3076N560O597S28
Isoelectric Point	6.09
Hydrophobicity	-0.311
Melting Point (℃)	58
Half Life	N.A.
Description	Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease	For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics	To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action	NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity	N.A.
Metabolism	N.A.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	37.6 Â± 13.1 mL/hr/kg [severe hemophilia A men]
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	Konyne 80 (factor ix complex)
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://www.rxlist.com/novoseven-drug/indications-dosage.htm
PubMed ID	16418464
3-D Structure	Th1032 (View) or (Download)

(6) Primary information
Entry 6
ID	1239
ThPP ID	Th1032
Therapeutic Peptide/Protein Name	Coagulation factor VIIa
Sequence	ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	45079.1
Chemical Formula	C1972H3076N560O597S28
Isoelectric Point	6.09
Hydrophobicity	-0.311
Melting Point (℃)	58
Half Life	N.A.
Description	Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease	For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics	To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action	NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity	N.A.
Metabolism	N.A.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	Profilnine SD (factor ix complex)
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	16418464
3-D Structure	Th1032 (View) or (Download)

(7) Primary information
Entry 7
ID	1240
ThPP ID	Th1032
Therapeutic Peptide/Protein Name	Coagulation factor VIIa
Sequence	ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	45079.1
Chemical Formula	C1972H3076N560O597S28
Isoelectric Point	6.09
Hydrophobicity	-0.311
Melting Point (℃)	58
Half Life	N.A.
Description	Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease	For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics	To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action	NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity	N.A.
Metabolism	N.A.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	Proplex T (factor ix complex)
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	16418464
3-D Structure	Th1032 (View) or (Download)

(8) Primary information
Entry 8
ID	1241
ThPP ID	Th1032
Therapeutic Peptide/Protein Name	Coagulation factor VIIa
Sequence	ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	45079.1
Chemical Formula	C1972H3076N560O597S28
Isoelectric Point	6.09
Hydrophobicity	-0.311
Melting Point (℃)	58
Half Life	N.A.
Description	Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/Disease	For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics	To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action	NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Toxicity	N.A.
Metabolism	N.A.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	Brilinta (ticagrelor)
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	16418464
3-D Structure	Th1032 (View) or (Download)